Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
Bagsværd, Denmark, 12 February 2024 -- This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.
The company's board members, executives and their associated persons have reported the transactions to Novo Nordisk and have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company's board members, executives and their associated persons.
Please find below a statement of such trading in shares issued by Novo Nordisk.
| Details of the person discharging managerial responsibilities/person closely associated | ||||||
| a) | Name of the Board member/Executive/Associated Person | Ludovic Helfgott | ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | Executive Vice President | ||||
| b) | Initial notification/Amendment | Initial notification | ||||
| 3 | Details of the issuer | |||||
| a) | Name | Novo Nordisk A/S | ||||
| b) | LEI | 549300DAQ1CVT6CXN342 | ||||
| 4 | Details of the transaction(s) | |||||
| a) | Description of the financial instrument, type of instrument, |
Shares |
||||
| Identification code | Novo Nordisk B DK0062498333 | |||||
| b) | Nature of the transaction | Sale of shares | ||||
| c) |
Price(s) and volume(s) |
|||||
| Price(s) | Volume(s) | |||||
| DKK 824.00 | 20,000 shares | |||||
| d) | Aggregated information Aggregated volumePrice | 20,000 shares DKK 824.00 |
||||
| e) | Date of the transaction | 2024-02-09 | ||||
| f) | Place of the transaction | Nasdaq Copenhagen | ||||
| Details of the person discharging managerial responsibilities/person closely associated | ||||||
| a) | Name of the Board member/Executive/Associated Person | Doug Langa | ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | Executive Vice President | ||||
| b) | Initial notification/Amendment | Initial notification | ||||
| 3 | Details of the issuer | |||||
| a) | Name | Novo Nordisk A/S | ||||
| b) | LEI | 549300DAQ1CVT6CXN342 | ||||
| 4 | Details of the transaction(s) | |||||
| a) | Description of the financial instrument, type of instrument, |
Shares |
||||
| Identification code | Novo Nordisk B DK0062498333 | |||||
| b) | Nature of the transaction | Sale of shares | ||||
| c) |
Price(s) and volume(s) |
|||||
| Price(s) | Volume(s) | |||||
| DKK 823.83 | 19,461 shares | |||||
| d) | Aggregated information Aggregated volumePrice | 19,461 shares DKK 823.83 |
||||
| e) | Date of the transaction | 2024-02-08 | ||||
| f) | Place of the transaction | Nasdaq Copenhagen | ||||
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 63,400 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.
Contacts for further information
| Media: | |
| Ambre James-Brown +45 3079 9289 abmo@novonordisk.com |
Elizabeth DeLuca (US) +1 609 580 9868 edel@novonordisk.com |
| Investors: | |
| Daniel Muusmann Bohsen +45 3075 2175 dabo@novonordisk.com |
Frederik Taylor Pitter +45 3075 8259 fptr@novonordisk.com |
| David Heiberg Landsted +45 3077 6915 dhel@novonordisk.com |
Mark Joseph Root (US) +1 848 213 3219 mjhr@novonordisk.com |
| Sina Meyer +45 3079 6656 azey@novonordisk.com |
Company Announcement No 13 / 2024
Attachment
\Hugin
Mest læste lige nu
Seneste nyheder
- 1 af 1189
- næste ›